Prescribing statins among patients with type 2 diabetes: The clinical gap between the guidelines and practice

Mohamed Anwar Hammad, Syed Azhar Syed Sulaiman, Nor Azizah Aziz, Dzul Azri Mohamed Noor
Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Malaysia, 1Endocrinology Clinics, Department of Internal Medicine, Penang General Hospital, Penang, Malaysia

Background: Statins are recommended for cardiovascular protection for people with diabetes (high-risk groups). This study aimed to evaluate the gap between the guidelines of statin utilization and clinical practice among outpatients with type 2 diabetes regarding the patient's age and gender, to assess if this preventive drug is being satisfactorily utilized or not. Materials and Methods: In this cross-sectional study, patients aged <40 or >75 years, pregnant patients, and patients with type 1 diabetes, human immunodeficiency virus, or liver cirrhosis were excluded. Demographics, laboratory parameters, and prevalence of exposure to statin therapy were evaluated. This study was guided by the 2013 American College of Cardiology/American Heart Association cholesterol guidelines. IBM SPSS software was used for data management. Results: The study cohort involved 576 patients, with age being 58.3 ± 8.9 years. There were 50.5% of females and 49.5% of males. Overall 81.1% of patients aged 58.8 ± 8.8 years were statin users and 18.9% of patients aged 56.2 ± 9 years were statin nonusers. About 83.2% of females and 78.9% of males were prescribed statins. Statin medications included simvastatin 79.2%, atorvastatin 11.6%, lovastatin 5.8%, rosuvastatin 2.1%, and pravastatin 1.3%. Statin users' and nonusers' adherence was 56.5%, and 41.3% (P = 0.004), respectively. The adherence to medication plan of females and males was 55.7% and 51.6%, respectively (P = 0.004). Conclusion: Patients with diabetes who are at high risk of cardiovascular events, exposure to statin treatment is significantly less than perfect position both in females and males. Nearly one-fifth of the patients with type 2 diabetes are not using statins despite therapeutic necessities.

Key words: Age, clinical gap, gender, Malaysia, practice guidelines, statin medication, type 2 diabetes

INTRODUCTION

Cardiovascular disease (CVD) affects one-third of patients and remains the main reason of death in the United States.[1] At the same time, diabetes mellitus is recognized as a hazard equivalent to coronary heart disease (CHD). Reaching treatment targets is essential in preventing further morbidity and mortality resulting from CVDs.[2,3] Some of the large-scale randomized controlled trials and observational studies have demonstrated the efficacy of statins in preventing cardiovascular morbidity and mortality in diabetic patients.[4] Therefore, statins have become the cornerstone of hypercholesterolemia pharmacotherapy in patients with diabetes. Clinical practice guidelines recommend using statins as the first choice of drug in patients with mixed dyslipidemia or hypercholesterolemia.[5]

The American Diabetes Association recommends that individuals with diabetes and a history of CVD aged from 40 to 75 years should be given a statin regardless of their baseline low-density lipoprotein cholesterol (LDL-C) concentration.[6] Many studies have confirmed that a significant proportion of patients with diabetes in the community do not reach the predefined goals for optimal management of blood glucose, lipids,
and blood pressure and suffer from comorbidities and polypharmacy. This failure to attain therapeutic targets has been reported in numerous researches from around the world, despite various patient populations, different clinical practice recommendations, and altered time frames.

This study was conducted to investigate the application of clinical practice guideline endorsements for the management of dyslipidemia in diabetic patients aged >40 and ≤75 years in actual practical clinical situations. At the same time, the study evaluates the gap between the guideline recommendation of statin utilization and practice among outpatients with type 2 diabetes mellitus with regard to their age and gender. The null hypothesis assumes that there is no gap between clinical practice and guidelines recommendations and also assumes no difference among females and males in the rate of prescribed statins.

MATERIALS AND METHODS

Study population
A cross-sectional study was conducted at the Endocrinology Clinic in Hospital Pulau Pinang, Malaysia, in October 2015–2016. The sociodemographic and prescription data for statin use were extracted from 827 patient files. The study enrolled individuals with type 2 diabetes mellitus aged 40–75 years. About 251 cases (186 patients <40 or >75 years old, 9 pregnant patients, 40 with type 1 diabetes, and 16 patients with liver cirrhosis) were excluded from the study. The experience of statin therapy in 576 patients was evaluated.

Procedure and variable assessment
A checklist was used for collecting patients’ Demographic characteristics include age, weight, height, gender, and ethnicity. The related clinical variables involve glycated hemoglobin (HbA1c), comorbidities, statin medications, and drug dosage and their duration. Data were collected from individuals, patients’ medical records, and medical team. The principal investigator collected the data. A diabetologist estimated patients’ adherence using 8-item Morisky Medication Adherence Scale. Adherence was classified as low adherence (scores >2), medium adherence (scores 1 or 2), and high adherence (scores = 0).

This study was guided by the 2013 American College of Cardiology/American Heart Association cholesterol guideline (AHA). Statin members were classified into high-dose intensity (HDI) group (atorvastatin 40–80 mg, rosuvastatin 20–40 mg, and simvastatin 60–80 mg daily), medium-dose intensity (MDI) group (atorvastatin 10–20 mg, lovastatin 40–60 mg, pravastatin 40–80 mg, rosuvastatin 5–10 mg, and simvastatin 20–40 mg daily), and low-dose intensity (LDI) group (simvastatin 10 mg, pravastatin 10–20 mg, and lovastatin 20 mg daily). Uncontrolled glycemia was defined as HbA1c >7% for patients aged <65 years and ≥8% for patients aged ≥65 years based on the guidelines of American Diabetes Association 2016. This study was guided by the reporting guidelines for cross-sectional studies and Strengthening the Reporting of Observational Studies in Epidemiology (STROBE).

Statistical analysis
The data were managed using IBM SPSS software version 23.0 (SPSS Statistics for Windows, IBM Corp., Armonk, NY, USA). The Kolmogorov–Smirnov test was used to evaluate normality of the variables. Log transformation was performed on some of the skewed variables before analysis to reach a normal distribution. Nominal variables were demonstrated as a number and percentage, n (%). Parametric data were illustrated as the mean ± standard deviation (SD). Independent t-test was conducted to estimate the differences of means among the normally distributed continuous factors such as age, body mass index (BMI), period of diabetes, and HbA1c%. Mann–Whitney U-test was used when the distribution was skewed. Chi-square test evaluated the differences between the nominal variables such as ethnicity, family history of diabetes, HbA1c control, adherence, statin use, and gender. Kendall’s tau_b or Spearman’s correlation analysis was done for evaluating the relationship between statins and the other study variables, as appropriate. Linear and multinomial logistic regression analyses were done to predict the variable sharing in the decrease or increase of the utilization of statins in the management of diabetic dyslipidemia. P < 0.05 was considered statistically significant.

Ethical consideration
From the ethical perspective, this study followed the procedures of the registration in Clinical Research Centre in Hospital Pulau Pinang and the registration in National Medical Research Register (NMRR ID: NMRR-15-1068-25700). In addition, participants have signed an informed consent form, and all of the study procedures were conducted under the supervision of experts. All phases of the study were accredited by the local health authorities and the institutional Medical Ethics Committee before the initiation of this study. The confidentiality, data, and dignity of the patients are protected and used for the research and publication only.

RESULTS
This study enrolled a total of 576 patients, in the age range of 40–75 years, with mean ± SD of 58.3 ± 8.9 years. There were 50.5% of females and 49.5% of males. Statin users constituted 81.1% of cases, with age being 58.8 ± 8.8 years.
Statin nonusers constituted 18.9% of patients, with a mean age of 56.2 ± 9 years. Around 83.2% of women and 78.9% of men were given statins. Statin medicines included atorvastatin 11.6%, lovastatin 5.8%, pravastatin 1.3%, rosuvastatin 2.1%, and simvastatin 79.2%, as described in Figure 1. About 16.7% of patients were prescribed HDI-statins, 19.3% were prescribed LDI-statins, and 64% were prescribed MDI-statins as shown in Figure 2. Statin users had high adherence (56.5%), while statin nonusers had high adherence (41.3%) (P = 0.004) as demonstrated in Table 1. The adherence to medication plan of females and males was 55.7% and 51.6%, respectively (P = 0.004) as described in Table 2.

Binary logistic regression confirmed BMI, history of diabetes incidence, diabetic family history, HbA1c%, and uncontrolled glycemia (HbA1c >7%) as negative predictors for the utilization of statins among diabetic patients, whereas adherence works as a positive predictor for the usage of statins in diabetic dyslipidemia management (all P < 0.05). However, age and ethnicity are not predictors for the use of statins among type 2 diabetic persons (P > 0.05) as illustrated in Table 3.

**DISCUSSION**

In this study, about 20% of patients with type 2 diabetes mellitus aged between 40 and 75 years were not prescribed a statin. Besides, females had more exposure to statin therapy than males.

A robust body of evidence supports the cardiovascular benefits of beginning statin treatment. A Cochrane review article based on 18 randomized controlled trials with a total of 56,934 patients found that statin therapy reduced all-cause mortality. In addition, statin therapy reduced fatal and nonfatal cardiovascular events and reduced the incidence of fatal and nonfatal stroke. Most of the standard clinical guidelines have recommended the utilization of statin treatment in patients with type 2 diabetes.¹²¹

In 2010, the Cholesterol Treatment Trialists’ collaboration achieved a meta-analysis of 26 trials with a total of more than 170,000 participants and follow-up of approximately 5 years. This meta-analysis found an overall decrease in all-cause mortality of 10% for every 1.0 mmol/L lessening in LDL-C levels (relative risk: 0.90, 95% confidence interval: 0.87–0.93) (P < 0.001). In addition, there were significant reductions in major vascular events.

**Table 1: Variable distribution between statin user group and statin nonuser group among diabetic patients**

| Variance                         | Statin users (n=467) | Nonstatin users (n=109) | P     |
|---------------------------------|----------------------|-------------------------|-------|
| Age (years)                     | 58.8±8.8             | 56.2±9                  | 0.007 |
| BMI (kg/m²)                     | 28.6±5.6             | 27.1±5.3                | 0.012 |
| Gender, n (%)                   |                      |                         |       |
| Male                            | 225 (48.2)           | 60 (55)                 | 0.803 |
| Female                          | 242 (51.8)           | 49 (45)                 | 0.803 |
| Ethnicity, n (%)                |                      |                         |       |
| Malay                           | 186 (39.8)           | 28 (25.7)               | 0.028 |
| Chinese                         | 151 (32.3)           | 48 (44)                 | 0.028 |
| Indian                          | 130 (27.8)           | 33 (30.3)               | 0.028 |
| Family history of diabetes, n (%)| 130 (27.8)           | 35 (32.1)               | 0.001 |
| Period of diabetes              | 14.5±8.2             | 11.1±7                  | 0.001 |
| HbA1c, n(%)                     | 349 (74.7)           | 39 (35.8)               | 0.001 |
| HbA1c, (mean ± SD)              | 8.6±1.9              | 7.2±1.4                 | 0.001 |
| High adherence, n (%)           | 264 (56.5)           | 45 (41.3)               | 0.004 |
| Medium adherence, n (%)         | 79 (16.9)            | 24 (22)                 | 0.004 |
| Low adherence, n (%)            | 124 (26.6)           | 40 (36.7)               | 0.004 |

Chi-square was used for nominal variables. Student t-test was performed for normally distributed variables. Mann–Whitney U-test was done for skewed variables. The P value is significant at level <0.05 (two tailed), data are presented as mean±SD or n (%). BMI=Body mass index; HbA1c=Glycated hemoglobin; SD=Standard deviation

**Figure 1:** Statin distribution among outpatients with type 2 diabetes mellitus

**Figure 2:** Distribution of statin dose intensity among outpatients with type 2 diabetes
Due to the overwhelming body of evidence supporting its use, statin therapy is recommended according to the guidelines of the AHA and the European Society of Cardiology.[22,23] In 2017, a study evaluated statin usage among people with diabetes and those with CHD in Vellore. Among 61 patients with CHD, 37.7% were on statins. Statin use among 422 persons with diabetes aged ≥40 years was 7.6% among rural patients and 13.4% among urban patients. Statin utilization for CHD was under 50% although higher than the use among people with diabetes, indicating the requirement to address this low percentage of usage among these high-risk cohorts.[24] In 2018, a national retrospective cohort of 899,664 veterans aged ≥40 years with diabetes mellitus (Brennan et al. 2018) [25].

Table 2: Distribution of variables between diabetic female and male cohorts

| Variance                  | Female (n=291) | Male (n=285) | P    |
|---------------------------|---------------|--------------|------|
| Age (years)               | 58±1±8.7      | 58±5±9.1     | 0.628|
| BMI (kg/m²)               | 28±2±5.6      | 28±5±5.5     | 0.584|
| Ethnicity, n (%)          |               |              |      |
| Malay                     | 117 (40.1)    | 97 (34)      | 0.028|
| Chinese                   | 99 (34.1)     | 100 (35.1)   | 0.028|
| Indian                    | 75 (25.8)     | 88 (30.9)    | 0.028|
| Family history of diabetes, n (%) | 89 (30.6)     | 76 (26.7)    | 0.001|
| Period of diabetes        | 14±1±7.7      | 13±7±8.4     | 0.517|
| HbA1c, n (%)              | 196 (73.6)    | 192 (67.4)   | 0.001|
| HbA1c, (mean ± SD)        | 8.5±1.9       | 8.3±1.8      | 0.233|
| High adherence, n (%)     | 162 (55.7)    | 147 (51.6)   | 0.004|
| Medium adherence, n (%)   | 47 (16.1)     | 56 (19.6)    | 0.004|
| Low adherence, n (%)      | 82 (28.2)     | 82 (28.8)    | 0.004|
| Statin users, n (%)       | 242 (83.2)    | 225 (78.9)   | 0.001|
| Statin nonuser, n (%)     | 49 (16.8)     | 60 (21.1)    | 0.001|

Chi-square was used for nominal variables. Student t-test was performed for normally distributed variables. Mann–Whitney U-test was done for skewed variables. The P value is significant at level <0.05 (two tailed); data are presented as mean±SD; or n (%). BMI=Body mass index; HbA1c=Glycated hemoglobin; SD=Standard deviation.

Table 3: Prediction of statin utilization in diabetic dyslipidemia management (n=576)

| Independent variables    | B     | SE    | Wald  | df   | P    | OR   | 95% CI for OR |
|--------------------------|-------|-------|-------|------|------|------|---------------|
| Age                      | −0.005| 0.016 | 0.088 | 1    | 0.767| 0.995| 0.964–1.027   |
| Adherence                | 0.675 | 0.165 | 16.795| 1    | 0.001| 1.964| 1.422–2.713   |
| BMI                      | −0.082| 0.026 | 9.737 | 1    | 0.002| 0.921| 0.875–0.970   |
| Diabetic family history  | −0.554| 0.274 | 4.072 | 1    | 0.044| 0.575| 0.336–0.984   |
| Diabetic period          | −0.048| 0.018 | 7.211 | 1    | 0.007| 0.953| 0.920–0.987   |
| Ethnicity                | 0.190 | 0.158 | 1.450 | 1    | 0.229| 1.209| 0.888–1.648   |
| HbA1c (%)                | −0.549| 0.107 | 26.514| 1    | 0.001| 0.578| 0.469–0.712   |
| HbA1c control            | −0.749| 0.299 | 6.279 | 1    | 0.012| 0.473| 0.263–0.850   |
| Constant                 | 6.398 | 1.452 | 19.426| 1    | 0.001|      |               |

Binary logistic regression was used to predict correlation. The P value is significant at level <0.05 (two tailed). Dependent variable=Statin usage; Independent variables=BMI, diabetic family history, diabetic period, HbA1c (%), HbA1c control. B=Intercept value; BMI=Body mass index; CI=Confidence interval; df=Degrees of freedom; HbA1c=Glycated hemoglobin; OR=Odds ratio; SE=Standard error.

Elnaem et al. (2017) evaluated the patterns of statin treatment prescribed among hospitalized individuals with type 2 diabetes mellitus. The study involved patients aged between 40 and 75 years. The assessment of statin prescription indicated that 35% of patients were not given any statin, opposing to the national treatment recommendations. About 26% of the study participants were prescribed medications that interacted with statins.[24] A significant percentage of the participants did not receive their recommended statin treatment for CVD avoidance, which is in concordance with our findings.[27]

Variance in drug disposition, pharmacodynamics, and physiology contribute to the statement that females and males frequently respond differently to drugs. Hormonal influences can play a significant role. Sex/gender dissimilarities in dyslipidemia management with statins and more considerable trouble in attainment of the goals can be partly related to the sex/gender physiopathological divergences. Evidence supporting sex-based differences in
statin metabolism implicate differences in body fat content between males and females.\[9\]

A recent systematic review and meta-analysis of 64 cohorts, including 858,507 persons and 28,203 coronary events, reported that females with diabetes have more than a 40% greater risk of incident CHD compared with diabetic males, this difference due to the higher percentage of females’ body fat.\[9\] The cause of these significant differences may partially stem from a shortage of control for cardiovascular hazard factors containing dyslipidemia among female patients with diabetes.\[30\]

A Spanish revision which comprised available data for a total of 286,791 patients described that, while the percentage of females given lipid-lowering prescriptions was comparable to or even higher than that of males, LDL-C levels were remarkably uncontrolled in both women with and without CVD.\[31\] These findings interpret the higher prevalence of statin use among females than males in our study.

**CONCLUSION**

People with type 2 diabetes mellitus who are at high risk of cardiovascular events, experience to statin treatment are significantly less than ideal condition both in males and females. Nearly 20% of the patients with type 2 diabetes are not using statins in spite of therapeutic necessities. Females were prescribed more statin than males. The utilization of statins decreases by the increase in BMI, diabetic period, HbA1c%, diabetic family history, and uncontrolled HbA1c. Efforts to confirm appropriate statin prescription and utilization can benefit in achieving better clinical outcomes of statin therapy and improve the patients’ quality of life.

**Study limitation**

The study was done in a single center, wherever the time was constrained, and information accessibility in Hospital Pulau Pinang limited this study.

**Acknowledgments**

The authors are appreciative to all of the staff at the Department of Endocrine, Department of Pharmacy and laboratory teams in Hospital Pulau Pinang for their kind help and support in facilitating this study. Special appreciations to Universiti Sains Malaysia for financially supporting this research.

**Financial support and sponsorship**

Universiti Sains Malaysia supported this research (USM Fellowship 4/15).

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Al-Kindi SG, DeCicco A, Longenecker CT, Dalton J, Simon DI, Zidar DA. Rate of statin prescription in younger patients with severe dyslipidemia. JAMA Cardiol 2017;2:451-2.
2. Yudin ZM, Yaacob LH, Hassan NB, Ismail SB, Draman N, Yusoff SS, et al. Achievement of LDL cholesterol goal and adherence to statin by diabetes patients in Kelantan. Malays J Med Sci 2017;24:44-50.
3. Hammad MA, Mohamed Noor DA, Syed Sulaiman SA. The effect of patients’ adherence on HbA1c control. AMPSR 2017;1:30-5.
4. Anderson TJ, Grégoire J, Pearson GJ, Barry AR, Couture P, Dawes M, et al. 2016 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2016;32:1263-82.
5. Hammad MA, Mohamed Noor DA, Syed Sulaiman SA, Khamis AA, Kharshid A, Aziz NA. Comparison of statins control in outpatients dose intensity on HbA1c with type 2 diabetes: A prospective cohort study. Int J Med Health Biomed Bioeng Pharm Eng 2017;11:423-8.
6. Subedi BH, Tota-Maharaj R, Silverman MG, Minder CM, Martin SS, Ashen MD, et al. The role of statins in diabetes treatment. Diabetes Spectr 2013;26:156-64.
7. Hammad MA, Khamis AA, Al-Akhali KM, Ali TM, Alasmri AM, Al-Ahmari EM, et al. Evaluation of drug dosing in renal failure. IOSR J Pharm Biol Sci 2016;11:39-50.
8. Alakhali KM, Solim M, Hammad MA. Evaluation of therapeutic drug monitoring of cyclosporine and tacrolimus in kidney transplant patients. J Phys Conf Sci 2014;3:18-25.
9. Hammad MA, Mohamed Noor DA, Syed Sulaiman SA, Elsayed TM. Statins effects on diabetic retinopathy among patients with type 2 diabetes mellitus. Int J Ophthalmol Vis Sci 2017;2:106-14.
10. Al Akhali K, Ali MA, Ansari MA. Evaluation of prevalence and pattern of anemia – A hospital based study in Aseer Province, Kingdom of Saudi Arabia. J Exp Med Surg Res 2013;2:32-35.
11. Khaled MA, Ansari A, Anwar HA. Analysis of prevalence, risk factor and pharmacotherapy of hypertension in outpatients. Indian J Pharm Pract 2013;6:64-7.
12. Elnaem MH, Mohamed MH, Huri HZ, Azarismn SM, Elkalmi RM. Statin therapy prescribing for patients with type 2 diabetes mellitus: A review of current evidence and challenges. J Pharm Bioalloide Sci 2017;9:80-7.
13. Janežič A, Locatelli I, Kos M. Criterion validity of 8-item Morisky Medication Adherence Scale in patients with asthma. PLoS One 2017;12:e0187835.
14. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2014;63:2889-934.
15. American Diabetes Association. Older adults, standards of medical care in diabetes–2016. Diabetes Care 2016;39 Suppl 1:S81-5.
16. STROBE Statement. STROBE Checklists. Checklist for Cross‑Sectional Studies; 2017. Available from: https://www.strobe‑statement.org/index.php?id=available‑checklists. [Last accessed on 2017 Feb 05].
17. Mazoochian L, Mohammad Sadeghi HM, Pourfarzam M. The effect of FADS2 gene rs174583 polymorphism on desaturase activities, fatty acid profile, insulin resistance, biochemical indices, and incidence of type 2 diabetes. J Res Med Sci 2018;23:47.
18. Chen SY, Du J, Lu NX, Xu JH. Platelet distribution width as a novel indicator of disease activity in systemic lupus erythematosus. J Res Med Sci 2018;23:48.
19. National Medical Research Register, National Institute of Health NIH Guideline. Available from: https://www.nmrr.gov.my/fwbLoginPage.jsp?fwbPageId=NMRR_Home. [Last accessed on 2018 Jan 07].

20. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013;1:CD004816. DOI: 10.1002/14651858.CD004816.pub5.

21. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670‑81.

22. Miller PE, Martin SS. Approach to statin use in 2016: An update. Curr Atheroscler Rep 2016;18:20.

23. Blackburn R, Osborn D, Walters K, Nazareth I, Petersen I. Statin prescribing for prevention of cardiovascular disease amongst people with severe mental illness: Cohort study in UK primary care. Schizophr Res 2018;192:219-25.

24. Oommen AM, Nand K, Abraham VJ, George K, Jose VJ. Prevalence of statin use among high-risk patients in urban and rural Vellore, Tamil Nadu: A population-based cross-sectional study. Indian J Pharmacol 2017;49:201-4.

25. Brennan MB, Huang ES, Lobo JM, Kang H, Guihan M, Basu A, et al. Longitudinal trends and predictors of statin use among patients with diabetes. J Diabetes Complications 2018;32:27-33.

26. Hammad MA, Tangisuran B, Kharshid AM, Abdul-Aziz N, Hassan Y, Aziz NA, et al. Drug-drug interaction-related uncontrolled glycemia. J Pharm Bioallied Sci 2017;9:221-8.

27. Elnaem MH, Nik Mohamed MH, Huri HZ, Azarisman SM. Patterns of statin therapy prescribing among hospitalized patients with type 2 diabetes mellitus in two Malaysian tertiary hospitals. Trop J Pharm Res 2017;16:3005-11.

28. Rossi MC, Cristofaro MR, Gentile S, Lucisano G, Manicardi V, Mulas MF, et al. Sex disparities in the quality of diabetes care: Biological and cultural factors may play a different role for different outcomes: A cross-sectional observational study from the AMD annals initiative. Diabetes Care 2013;36:3162-8.

29. Peters SA, Huxley RR, Woodward M. Diabetes as risk factor for incident coronary heart disease in women compared with men: A systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia 2014;57:1542-51.

30. Lewey J, Shrank WH, Bowry AD, Kilabuk E, Brennan TA, Choudhry NK, et al. Gender and racial disparities in adherence to statin therapy: A meta-analysis. Am Heart J 2013;165:665-78, 678.e1.

31. Gibson DM, Bron NJ, Richens A, Hounslow NJ, Sedman AJ, Whitfield LR, et al. Effect of age and gender on pharmacokinetics of atorvastatin in humans. J Clin Pharmacol 1996;36:242-6.